Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 22;2:20–32. doi: 10.1016/j.jvssci.2020.10.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 6 — Gene therapy with E-selectin/adeno-associated virus (AAV) increased recruitment of endothelial progenitor cells (EPCs) in ischemic tissue. A, Representative images of immunofluorescent staining of CD34 (green) and CD31 (red) of ischemic muscle tissues of E-selectin/AAV–treated mice and LacZ/AAV–treated mice. E-selectin/AAV–treated ischemic tissue demonstrates increased expression of CD34 and CD31. B, Quantitative levels of CD34/CD31 per image in mice undergoing E-selectin/AAV treatment vs LacZ/AAV treatment. Student's t test revealed a significant increase in CD34/CD31 levels in E-selectin/AAV–treated ischemic tissue vs LacZ/AAV–treated ischemic tissue (P < .05). E-selectin/AAV sections, n = 15; LacZ/AAV sections, n = 15.